Sandoz Group (OTCMKTS:SDZNY) Upgraded to “Strong-Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Sandoz Group (OTCMKTS:SDZNY) from a hold rating to a strong-buy rating in a research report released on Thursday morning,Zacks.com reports.

Sandoz Group Trading Up 5.4%

Shares of SDZNY stock opened at $85.99 on Thursday. The company has a current ratio of 1.29, a quick ratio of 0.82 and a debt-to-equity ratio of 0.62. The firm has a 50-day moving average of $76.24 and a 200-day moving average of $67.30. Sandoz Group has a one year low of $35.61 and a one year high of $86.80.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.